Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effect of Exenatide Compared to Insulin Glargine on Cardiac Function and Metabolism in Type 2 Diabetic Patients With Congestive Heart Failure (NYHA II): a Randomized Comparator-Controlled Trial.

Next Previous
Trial Profile

The Effect of Exenatide Compared to Insulin Glargine on Cardiac Function and Metabolism in Type 2 Diabetic Patients With Congestive Heart Failure (NYHA II): a Randomized Comparator-Controlled Trial.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics

Most Recent Events

  • 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 08 May 2012 Planned end date changed from 1 Mar 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
  • 19 Apr 2011 Planned End Date changed from 1 Jun 2011 to 1 Mar 2012, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top